Literature DB >> 11055466

The role of ambulatory blood pressure monitoring in elderly hypertensive patients.

G Mancia1, G Parati.   

Abstract

There is strong evidence that ambulatory blood pressure measurements show only limited agreement with blood pressures measured in the clinic ("office" blood pressures), and are more relevant to the prognosis of hypertension. Several markers of end-organ damage, for example, have been shown to correlate more strongly with 24-h blood pressure than with office blood pressure. In addition, end-organ damage has been shown to be correlated with 24-h blood pressure variability. Ambulatory blood pressure monitoring (ABPM) has revealed a number of differences between the blood pressure profiles of elderly and younger patients. Since 24-h blood pressure control is now widely accepted as an important goal of antihypertensive therapy, ABPM has a potentially useful role in monitoring treatment in clinical trials in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055466

Source DB:  PubMed          Journal:  Blood Press Suppl        ISSN: 0803-8023


  4 in total

Review 1.  Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.

Authors:  Stefano Omboni; Ettore Malacco; Jean-Michel Mallion; Paolo Fabrizzi; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-01-17

2.  Predictors for the white coat effect in general practice patients with suspected and treated hypertension.

Authors:  Morten Lindbaek; Endre Sandvik; Kåre Liodden; Johnny Mjell; Kai Ravnsborg-Gjertsen
Journal:  Br J Gen Pract       Date:  2003-10       Impact factor: 5.386

3.  Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients : A Randomised, Double-Blind, Multicentre Study.

Authors:  Ettore Malacco; Simona Piazza; Stefano Omboni
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 4.  Role of angiotensin II type 1 receptor antagonists in the treatment of hypertension in patients aged >or=65 years.

Authors:  Alan H Gradman
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.